Menu
home
about us
Investment Approach
Client Service Approach
Market Analysis Summary
Mission Statement
Value Proposition
Team Biographies
Firm ADV PDFs
Form CRS
Firm Brochure-Part 2A of Form ADV
Brochure Supplement Amit Stavinsky
Brochure Supplement Frank Parks
Brochure Supplement Dominick Savo
Brochure Supplement Richard Mason
Brochure Supplement Joe Estes
Brochure Supplement Jonathan Ezra
Statement Of Financial Strength
Job Opportunities
Tamar Advisors
Own Your Practice
Letter to Clients
member log-in
contact us
PRODUCTS
Fixed Income Portfolio (FIP)
FIP Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Market (TAM)
TAM sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Fund (TAF)
TAF sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Market Value Securities (MVS)
MVS Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Value (TAV)
TAV Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Municipal Bonds
Taxable Bonds
Par, Premium, and Discount Bonds
Rating and Analyzing Bonds
Refunding & Pre-refunding
Bond Yields
Yield Curve
Secured Bonds
Mortgage Bonds
Unsecured Bonds
Debentures
Subordinated Debentures
Zero-Coupon Bonds
Convertible Bonds
High Yield Dividend Stocks
Independent Money Managers
Fees & Compensation
Corporate Cash Management
Fees & Compensation
Estate Planning
Financial Planning
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
Professional Alliance Network
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
MUNICIPAL BONDS
Municipal Bond Presentation
About Us
The Management
Global Asset Allocation Products
FIP Program
Classifying Municipal Bonds
Revenue Bonds
Credit Factors Affecting General Obligation Bonds
Credit Factors Affecting the Quality of Local Municipal Bonds
Analyzing the Credit Quality of General Obligation Bonds
Analyzing the Credit Quality of Revenue Municipal Bonds
What We Buy Currently
What We Normally Don’t Buy
Municipal Bonds – Unique Asset Class
Default Rates
Yield Difference
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same-Day Allocation
TSL’s Turnkey Operation Platform
Sample Portfolio
Sample Portfolio Analysis
Classifying Municipal Bonds
Revenue Municipal Bonds
Types of Revenue Municipal Bonds
Industrial Development Revenue Bonds
Lease-back Bonds
Special Tax Bonds
NHA/PHA Bonds
Moral Obligation Bonds
Municipal Notes
TANs/RANs
BANs
CLNs/GANs
Variable Rate Bonds/Notes
Build America Bonds
Double-Barreled Bonds
Bond Index Components
Open-end-Closed-end-Indenture
Sinking Fund
Bond Contracts
Bond Indenture
Official Statement
Bond Issuance Process
Analyzing GO Bonds
Analyzing Revenue Bonds
Debt Ratios
General Price Analysis of Municipal Bonds
Liquidity
Interest Rate Risk
Credit Risk
Coupon Risk
Maturity Risk
Municipal Bond Insurance
Municipal Bonds Unique Asset Class
Default Rates
What We Buy Currently
What We Normally Don’t Buy
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same Day Allocation
Traditional Broker/Dealer Execution Flow
TSL's Turnkey Operation Platform
INDEX FUNDS
Total Asset Fund (TAF)
TAF sm Program
Services, Fees and Compensation
Account Requirements
Client Information
Client Contact with Portfolio Manager(s)
Additional Information
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
EVENTS
FIP
Event Schedule
Municipal Bond Presentation
TAM
Event Schedule
Total Asset Market (TAM sm) Presentation
TAF
Event Schedule
Total Asset Fund (TAF sm) Presentation
MVS
Event Schedule
Market Value Securities (MVS sm) Presentation
Featured Event
Calendar of Events
Events History
Investing During Uncertain Times
Read FULL Seminar Here
Tax-Free Income Seminar
Bond Fund Seminar
RSVP-Signup Form
MARKET RESEARCH
Featured Quarterly Newsletter
Featured Articles
Contrarian Notes Blog
home
about us
Investment Approach
Client Service Approach
Market Analysis Summary
Mission Statement
Value Proposition
Team Biographies
Firm ADV PDFs
Form CRS
Firm Brochure-Part 2A of Form ADV
Brochure Supplement Amit Stavinsky
Brochure Supplement Frank Parks
Brochure Supplement Dominick Savo
Brochure Supplement Richard Mason
Brochure Supplement Joe Estes
Brochure Supplement Jonathan Ezra
Statement Of Financial Strength
Job Opportunities
Tamar Advisors
Own Your Practice
Letter to Clients
member log-in
contact us
PRODUCTS
Fixed Income Portfolio (FIP)
FIP Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Market (TAM)
TAM sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Fund (TAF)
TAF sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Market Value Securities (MVS)
MVS Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Value (TAV)
TAV Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Municipal Bonds
Taxable Bonds
Par, Premium, and Discount Bonds
Rating and Analyzing Bonds
Refunding & Pre-refunding
Bond Yields
Yield Curve
Secured Bonds
Mortgage Bonds
Unsecured Bonds
Debentures
Subordinated Debentures
Zero-Coupon Bonds
Convertible Bonds
High Yield Dividend Stocks
Independent Money Managers
Fees & Compensation
Corporate Cash Management
Fees & Compensation
Estate Planning
Financial Planning
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
Professional Alliance Network
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
MUNICIPAL BONDS
Municipal Bond Presentation
About Us
The Management
Global Asset Allocation Products
FIP Program
Classifying Municipal Bonds
Revenue Bonds
Credit Factors Affecting General Obligation Bonds
Credit Factors Affecting the Quality of Local Municipal Bonds
Analyzing the Credit Quality of General Obligation Bonds
Analyzing the Credit Quality of Revenue Municipal Bonds
What We Normally Buy
What We Normally Don’t Buy
Municipal Bonds – Unique Asset Class
Default Rates
Yield Difference
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same-Day Allocation
TSL’s Turnkey Operation Platform
Classifying Municipal Bonds
Revenue Municipal Bonds
Types of Revenue Municipal Bonds
Industrial Development Revenue Bonds
Lease-back Bonds
Special Tax Bonds
NHA/PHA Bonds
Moral Obligation Bonds
Municipal Notes
TANs/RANs
BANs
CLNs/GANs
Variable Rate Bonds/Notes
Build America Bonds
Double-Barreled Bonds
Bond Index Components
Open-end-Closed-end-Indenture
Sinking Fund
Bond Contracts
Bond Indenture
Official Statement
Bond Issuance Process
Analyzing GO Bonds
Analyzing Revenue Bonds
Debt Ratios
General Price Analysis of Municipal Bonds
Liquidity
Interest Rate Risk
Credit Risk
Coupon Risk
Maturity Risk
Municipal Bond Insurance
Municipal Bonds Unique Asset Class
Default Rates
What We Buy Currently
What We Normally Don’t Buy
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same Day Allocation
Traditional Broker/Dealer Execution Flow
TSL's Turnkey Operation Platform
INDEX FUNDS
Total Asset Fund (TAF)
TAF® Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Additional Information
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
EVENTS
FIP
Event Schedule
TAM
Event Schedule
Total Asset Market (TAM sm) Presentation
TAF
Event Schedule
Total Asset Fund (TAF sm) Presentation
MVS
Event Schedule
Market Value Securities (MVS sm) Presentation
Featured Event
Calendar of Events
Events History
Investing During Uncertain Times
Read FULL Seminar Here
Tax-Free Income Seminar
Bond Fund Seminar
RSVP-Signup Form
MARKET RESEARCH
Featured Quarterly Newsletter
Featured Articles
Contrarian Notes Blog
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Medpace Holdings, Inc. - Common Stock
(NQ:
MEDP
)
561.65
-7.20 (-1.27%)
Streaming Delayed Price
Updated: 4:00 PM EST, Dec 31, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Medpace Holdings, Inc. - Common Stock
< Previous
1
2
3
4
5
6
7
8
9
...
12
13
Next >
Medpace Holdings, Inc. to Report First Quarter 2025 Financial Results on April 21, 2025
March 18, 2025
From
Medpace Holdings, Inc.
Via
Business Wire
Drug Development Inputs & Services Stocks Q4 Results: Benchmarking Fortrea (NASDAQ:FTRE)
March 18, 2025
Let’s dig into the relative performance of Fortrea (NASDAQ:FTRE) and its peers as we unravel the now-completed Q4 drug development inputs & services earnings season.
Via
StockStory
A Look Back at Drug Development Inputs & Services Stocks’ Q4 Earnings: Repligen (NASDAQ:RGEN) Vs The Rest Of The Pack
March 11, 2025
As the Q4 earnings season comes to a close, it’s time to take stock of this quarter’s best and worst performers in the drug development inputs & services industry, including Repligen (NASDAQ:RGEN) and...
Via
StockStory
Spotting Winners: Charles River Laboratories (NYSE:CRL) And Drug Development Inputs & Services Stocks In Q4
March 05, 2025
Looking back on drug development inputs & services stocks’ Q4 earnings, we examine this quarter’s best and worst performers, including Charles River Laboratories (NYSE:CRL) and its peers.
Via
StockStory
$100 Invested In This Stock 5 Years Ago Would Be Worth $400 Today
↗
October 22, 2024
Via
Benzinga
2 Reasons to Watch MEDP and 1 to Stay Cautious
March 03, 2025
Medpace has been treading water for the past six months, recording a small loss of 4.4% while holding steady at $334.43. The stock also fell short of the S&P 500’s 7.6% gain during that period.
Via
StockStory
Topics
Stocks
Why Medpace (MEDP) Shares Are Trading Lower Today
February 11, 2025
Shares of clinical research company Medpace Holdings (NASDAQ:MEDP) fell 8.7% in the pre-market session after the company reported weak fourth-quarter results: Medpace's full-year revenue, EPS, and...
Via
StockStory
Harmonic Issues Weak Guidance, Joins Fluence Energy, Amkor Technology And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
↗
February 11, 2025
Via
Benzinga
Stay updated with the stocks that are on the move in today's after-hours session.
↗
February 10, 2025
The regular session of the US market on Monday is now over, but let's get a preview of the after-hours session and explore the top gainers and losers driving the post-market movements.
Via
Chartmill
Medpace Stock Falls On Q4 Earnings: The Details
↗
February 10, 2025
Medpace Holdings Inc (NASDAQ:MEDP) reported fourth-quarter financial results after the market close on Monday. Here's a rundown of the report.
Via
Benzinga
Medpace (NASDAQ:MEDP) Posts Q4 Sales In Line With Estimates But Stock Drops
February 10, 2025
Clinical research company Medpace Holdings (NASDAQ:MEDP) met Wall Street’s revenue expectations in Q4 CY2024, with sales up 7.7% year on year to $536.6 million. On the other hand, the company’s...
Via
StockStory
Medpace Holdings, Inc. Reports Fourth Quarter and Full Year 2024 Results
February 10, 2025
From
Medpace Holdings, Inc.
Via
Business Wire
Medpace (MEDP) To Report Earnings Tomorrow: Here Is What To Expect
February 09, 2025
Clinical research company Medpace Holdings (NASDAQ:MEDP) will be announcing earnings results tomorrow after market hours. Here’s what to expect.
Via
StockStory
Medpace Holdings, Inc. to Report Fourth Quarter and Fiscal Year 2024 Financial Results on February 10, 2025
January 02, 2025
From
Medpace Holdings, Inc.
Via
Business Wire
Earnings Scheduled For February 10, 2025
↗
February 10, 2025
Via
Benzinga
Medpace Holdings, Inc. Is Being Investigated For Securities Fraud And Investors With Losses Are Urged To Contact The Schall Law Firm
December 16, 2024
Via
ACCESSWIRE
The Schall Law Firm Invites Shareholder Contributions To An Inquiry Into Medpace Holdings Inc For Securities Law Violations
December 15, 2024
Via
ACCESSWIRE
Medpace Holdings, Inc. Is Being Investigated For Possible Securities Fraud And Affected Investors Are Urged To Contact The Schall Law Firm
December 14, 2024
Via
ACCESSWIRE
The Schall Law Firm Invites Shareholder Participation In An Inquiry Into Medpace Holdings Inc For Securities Law Violations
December 13, 2024
Via
ACCESSWIRE
Medpace Holdings, Inc. Is Being Investigated For Securities Fraud And Investors With Losses Are Urged To Contact The Schall Law Firm
December 12, 2024
Via
ACCESSWIRE
10 Health Care Stocks Whale Activity In Today's Session
↗
December 05, 2024
Via
Benzinga
MEDPACE ALERT: Bragar Eagel & Squire, P.C. is Investigating Medpace Holdings, Inc. on Behalf of Medpace Stockholders and Encourages Investors to Contact the Firm
November 12, 2024
From
Bragar Eagel & Squire
Via
GlobeNewswire
MEDP INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into Medpace Holdings, Inc. and Encourages Investors to Contact the Firm
November 08, 2024
From
Bronstein, Gewirtz & Grossman, LLC
Via
Business Wire
MEDP INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into Medpace Holdings, Inc. and Encourages Investors to Contact the Firm
October 31, 2024
From
Bronstein, Gewirtz & Grossman, LLC
Via
Business Wire
Bragar Eagel & Squire, P.C. Is Investigating Aviat, Medpace, Customers Bancorp, and Ibotta and Encourages Investors to Contact the Firm
October 29, 2024
From
Bragar Eagel & Squire
Via
GlobeNewswire
MEDP Investors Have Opportunity to Join Medpace Holdings, Inc. Fraud Investigation with the Schall Law Firm
October 23, 2024
From
The Schall Law Firm
Via
Business Wire
This McDonald's Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Wednesday
↗
October 23, 2024
Via
Benzinga
NASDAQ: MEDP Investigation Alert: Kessler Topaz Meltzer & Check, LLP Encourages Medpace Holdings, Inc. (NASDAQ: MEDP) Investors with Significant Losses to Contact the Firm
October 22, 2024
From
Kessler Topaz Meltzer & Check, LLP
Via
Business Wire
Why Is Medpace Stock Diving On Tuesday?
↗
October 22, 2024
Medpace Holdings reports Q3 results with revenue of $533.3M, below consensus. Backlog and EBITDA increased. Medspace lowered its FY24 revenue forecast.
Via
Benzinga
How Medpace Just Blew Up Expectations For Double-Digit Sales Growth In 2025
↗
October 22, 2024
The contract research organization missed bookings expectations, but didn't offer into any insight into the impact for 2025.
Via
Investor's Business Daily
< Previous
1
2
3
4
5
6
7
8
9
...
12
13
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.